Novavax, Inc.

NASDAQ (USD): Novavax, Inc. (NVAX)

Last Price

8.54

Today's Change

-0.01 (0.11%)

Day's Change

8.54 - 8.56

Trading Volume

71,045

Overview

Market Cap

1 Billion

Shares Outstanding

160 Million

Avg Volume

4,833,060

Avg Price (50 Days)

8.70

Avg Price (200 Days)

10.80

PE Ratio

-3.88

EPS

-2.18

Earnings Announcement

26-Feb-2025

Previous Close

8.55

Open

8.54

Day's Range

8.44 - 8.56

Year Range

3.53 - 23.86

Trading Volume

162,753

Price Change Highlight

1 Day Change

-1.17%

5 Day Change

-10.58%

1 Month Change

-8.45%

3 Month Change

-16.75%

6 Month Change

-48.60%

Ytd Change

-1.40%

1 Year Change

94.70%

3 Year Change

-91.42%

5 Year Change

76.78%

10 Year Change

-93.80%

Max Change

-89.44%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment